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Abstract
Purpose The aim of this study was to examine the rate and
timing of hemoglobin decline from <10 g/dL to <9 g/dL in
cancer patients receiving chemotherapy.
Methods Pooled data from the placebo arms of six random-
ized, controlled trials (RCTs) of darbepoetin alfa and data
from an aggregated US community oncology clinic elec-
tronic medical records (EMR) database were analyzed.
Patients had baseline hemoglobin ≥10 g/dL (RCTs) or base-
line hemoglobin between ≥10 g/dL and <11 g/dL (EMR
episodes) that declined to <10 g/dL at least once during the
study period. The proportion of patients/episodes with he-
moglobin decline to <9 g/dL by 3, 6, and 9 weeks without
erythropoiesis-stimulating agents was estimated from data
in each of the data sources, as was the rate of transfusions in
the RCTs.
Results Data from 411 patients receiving placebo in the
RCTs and 10,523 patients (10,942 episodes) in the EMR
database were analyzed. Forty percent and 35 % of RCT
patients and EMR episodes, respectively, had a hemoglobin
decline from <10 g/dL to <9 g/dL at week 3, 54 % and 43 %
at week 6, and 58 % and 46 % at week 9. Of patients in the
RCTs, 43 % required an RBC transfusion.
Conclusions Hemoglobin can rapidly decline in cancer
patients receiving chemotherapy with hemoglobin levels
around 10 g/dL, particularly in patients ≥65 years of age.
The rapid rate of hemoglobin decline in these patients
should be considered for optimal anemia management.
Keywords Anemia . Hemoglobin . Chemotherapy .
Transfusion . Elderly
Introduction
Anemia is common in cancer patients receiving chemother-
apy and is associated with poor clinical outcomes [1].
Chemotherapy-induced anemia can be treated with
erythropoiesis-stimulating agents (ESAs), red blood cell
(RBC) transfusions, or both. According to current ESA
labels, treatment with ESAs in patients receiving chemo-
therapy should not be considered until hemoglobin levels
are less than 10 g/dL in the USA or at or below 10 g/dL in
the EU [2–4]. However, ESAs take time to induce a hemo-
globin response and therefore are not suitable for patients
who require immediate correction of anemia [5]. Studies
have suggested that initiating an ESA when hemoglobin is
between 9 g/dL and 10 g/dL results in fewer transfusions
compared with initiating an ESAwhen hemoglobin is <9 g/
dL [6–8]. However, not all patients whose hemoglobin is in
the 9 g/dL to 10 g/dL range will continue to fall to levels of





M. Pirolli : J. Quigley : S. Hulnick
SDI Health,
One IMS Drive,
Plymouth Meeting, PA 19462, USA
J. Legg :H. Collins
Amgen Inc.,
One Amgen Center Drive,






Department of Medicine I, Medical University Vienna,
Vienna, Austria
e-mail: robert.pirker@meduniwien.ac.at
Support Care Cancer (2013) 21:987–992
DOI 10.1007/s00520-012-1617-2
to initiate an ESA is partially informed by the rate of
hemoglobin decline and the likelihood that the patient will
require a transfusion if they do not receive the ESA. Few
data are available regarding the proportion of patients with
hemoglobin in the range of 9 g/dL to <10 g/dL who will
experience a hemoglobin decline to <9 g/dL or the rate at
which the decline occurs. A better understanding of factors
that influence the rate of hemoglobin decline from 10 g/dL
to 9 g/dL may assist oncologists in optimizing the use of
ESAs in patients receiving chemotherapy.
We examined rates of hemoglobin decline using two types
of data: (1) from patients enrolled in randomized, placebo-
controlled clinical trials (RCTs) and (2) from community
oncology clinic electronic medical records (EMRs). RCTs
with placebo control are usually considered the gold standard
of clinical evidence; however, results from these trials, which
were initiated in the late 1990s, may not reflect real-world
contemporary oncology care in 2012. The purpose of this
analysis was to estimate the proportion of patients from
pooled data from six RCTs whose hemoglobin declined from
a level of <10 g/dL to <9 g/dL and the proportion of patients
who further declined to a level that required a transfusion in
the absence of treatment with an ESA. As these data were up
to 10 years old, we wanted to determine if these results would
also be applicable to a contemporary USA patient population
and therefore performed the same analysis using data from an
EMR database; transfusions are not routinely collected in
outpatient EMRs, so the transfusion endpoint could not be
evaluated in the patients in the EMR database.
Patients and methods
Study design
We analyzed data from two sources: pooled data from the
placebo arms of six RCTs of darbepoetin alfa and data from
an aggregated US community oncology clinic EMR data-
base maintained by SDI Health. The EMR database includ-
ed 385,000 annual cancer patients from the USA who had
documented hemoglobin values. Data used in this analysis
were obtained from 63 outpatient oncology practices.
Patients
The darbepoetin alfa RCTs included patients with solid
tumors [9], lung cancer [10, 11], lymphoproliferative malig-
nancies [12, 13], and multiple tumor types [14]. The subset
of placebo patients in these studies who had a baseline
hemoglobin ≥10 g/dL and reported at least one hemoglobin
value <10 g/dL during the study treatment period (length of
trial was 16 weeks for five RCTs and 24 weeks for one
RCT) were included in the analysis. In the original studies,
patients had a baseline hemoglobin level of ≤11.0 g/dL in
four studies [9, 10, 12, 13], <11.0 g/dL in one study [14],
and ≥9 g/dL in one study [11].
To closely mirror the criteria of the RCTs, eligible
patients in this analysis from the EMR database were
≥18 years old with nonmyeloid malignancies and index
hemoglobin ≥10 g/dL and <11 g/dL on or after the start of
the chemotherapy episode, with an index hemoglobin date
between August 1, 2008 and June 26, 2010. EMR-eligible
patients also had received a myelosuppressive chemothera-
py doublet (two chemotherapy drugs) between August 1,
2008 and June 26, 2010. Patients could be on any cycle of
their chemotherapy regimen as long as they received ≥2
additional chemotherapy cycles at ≤35-day intervals after
their index hemoglobin level of 10 g/dL to 11 g/dL. Che-
motherapy episodes were re-indexed when the hemoglobin
level was <10 g/dL to estimate the proportions of episodes
and patients that further declined to hemoglobin <9 g/dL by
3, 6, and 9 weeks without ESA therapy.
EMR-eligible patients could not have received an ESA
within 9 weeks before the date when hemoglobin was 10 g/
dL to 11 g/dL or at any time during the 18-week study
period unless hemoglobin was <9 g/dL. The doublet che-
motherapy regimen contained one drug from one of the
following categories: anthracycline (doxorubicin, epirubi-
cin, mitoxantrone, liposomal doxorubicin), taxane (paclitax-
el, docetaxel, nanoparticle albumin-bound [nab]-paclitaxel),
platinum (cisplatin, carboplatin, not oxaliplatin), or gemci-
tabine. These doublets were chosen to be consistent with a
prior non-Amgen publication that analyzed chemotherapy-
induced anemia prevalence and incidence in the USA [15].
Chemotherapy was administered at ≤35-day intervals during
the first 9 weeks of the study period or until hemoglobin
declined to <9 g/dL, whichever occurred first.
Study endpoints
For patients enrolled in the RCTs, study endpoints included the
occurrence of hemoglobin decline from <10 g/dL to <9 g/dL or
transfusion by weeks 3, 6, and 9 after hemoglobin <10 g/dL
was reached. For patients included in the EMR database, study
endpoints were the proportion of patients with hemoglobin
decline from the 10 g/dL to 11 g/dL range to <10 g/dL within
3, 6, and 9 weeks and of those episodes with hemoglobin
<10 g/dL, further hemoglobin decline to <9 g/dL within 3, 6,
and 9 weeks. EMR databases do not reliably capture trans-
fusions that occur outside the clinic setting, and transfusions
were therefore not evaluated for patients in the EMR database.
Statistical considerations
Kaplan–Meier point estimates and associated 95 % confi-
dence intervals (CIs) were provided for time-to-event
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analyses for patients enrolled in the RCTs. Data were stratified
by sex, age (<65 and ≥65 years), tumor type, and chemother-
apy type (platinum and other). EMR data were also stratified
by sex, age, tumor type, and chemotherapy type (platinum,
taxane, anthracycline, or gemcitabine). Index hemoglobin
date was defined as the date of first qualifying hemoglobin
level (≥10 g/dL and <11 g/dL within 7 days of chemotherapy
administration). Index chemotherapy date was defined as the
date chemotherapy was received.
Results
Patients
This analysis included 411 placebo patients who had base-
line hemoglobin ≥10 g/dL and at least one hemoglobin
value <10 g/dL enrolled in RCTs and 10,523 patients (rep-
resenting 10,942 chemotherapy episodes) with hemoglobin
≥10 g/dL and <11 g/dL in the EMR database. Approximate-
ly half of the patients enrolled in the RCTs were men (59 %)
and patients represented in the EMR database were predom-
inantly women (72 %) (Table 1). Similar proportions of
patients were ≥65 years of age (43 % of patients in the
RCTs and 39 % of patients in the EMR database). Tumor
types differed between the RCT and EMR patients; the
predominant tumor types were lung cancer and breast cancer
in the RCTs and EMR database, respectively. Chemotherapy
regimens differed between the two sets of patients; most
(78 %) patients in the RCTs received platinum-based regi-
mens compared with 58.6 % of patients in the EMR data-
base. Additionally, 66.4 % of patients in the EMR database
received taxane-based chemotherapy (patients in the EMR
database could be counted in more than one chemotherapy
category; e.g., carboplatin and paclitaxel would be included
in both “platinum” and “taxane” categories).
Hemoglobin decline
Similar proportions of patients in the RCTs and EMR database
experienced a decline in hemoglobin to <9 g/dL at weeks 3, 6,
and 9 (Table 2). Because the majority of placebo patients in
the RCTs had received a platinum and/or had lung cancer,
patients who received a platinum and/or had lung cancer in the
EMR database were analyzed separately; similar proportions
of such patients in the RCTs and episodes in the EMR
Table 1 Patient demographics
and disease characteristics at
baseline
aIncludes only patients who had
hemoglobin ≥10 g/dL and had
hemoglobin <10 g/dL at least
once during the study
SD standard deviation
RCT randomized controlled trials
EMR electronic medical records
RCT patientsa EMR patients
Placebo (N0411) All patients (N010,523) All episodes (N010,942)
Women, n (%) 168 (41) 7,565 (72) 7,825 (72)
Age, mean years (SD) 62.5 (10.1)
Age ≥65 years, n (%) 175 (43) 4,147 (39) 4,321 (39)
Race, White n (%) 397 (97)
Tumor type, n (%)
Breast 18 (4) 4,353 (41) 4,418 (40)
Gastrointestinal 14 (3)
Genitourinary 5 (1)
Gynecologic 12 (3) 899 (9) 961 (9)
Hematologic 56 (14)
Lung 297 (72) 3,071 (29) 3,257 (30)
Other 9 (2) 2,200 (21) 2,306 (21)
Stage, n (%)
I/II or lower/limited 39 (10)
III/IV or higher/extensive 361 (88)
Other 6 (1)
Unknown 5 (1)
Chemotherapy regimen, n (%)
Anthracycline 3,017 (29) 3,050 (28)
Taxane 7,075 (67) 7,269 (66)
Platinum 6,100 (58) 6,408 (59)
Gemcitabine 1,465 (14) 1,504 (14)
Hemoglobin, mean g/dL (SD) 11.26 (0.98)
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database had a hemoglobin decline from <10 g/dL to
<9 g/dL. Most events of hemoglobin decline to <9 g/dL
occurred within 3 weeks of chemotherapy, including
40 % of patients in the RCTs and 35 % of episodes
in the EMR database. Within 9 weeks, hemoglobin had
declined to <9 g/dL in 58 % of patients in the RCTs
(Fig. 1) and 46 % of episodes in the EMR database.
The percentage (95 % CI) of chemotherapy episodes in
the EMR database with a decline in hemoglobin to <9 g/dL
within 3 weeks was 38.3 % (6.3, 40.3) for patients 65 years
of age and older and 33.5 % (31.9, 35.2) for patients under
65 years of age (Fig. 2). At 9 weeks, the percentages (95 %
CI) were 49.0 % (46.9, 51.1) and 43.4 % (41.8, 45.1) for
episodes with a decline in hemoglobin to <9 g/dL for
patients ≥65 years and <65 years, respectively.
RBC transfusion
Of the 411 placebo patients enrolled from the RCTs, 178
(43%) required an RBC transfusion for their anemia (Table 3).
By week 9, over one third of patients (39 %) had undergone at
least one RBC transfusion.
Discussion
Not all patients on chemotherapy whose hemoglobin has
declined to the 9 g/dL to 10 g/dL range will continue to fall
to levels of <9 g/dL or require a transfusion. Determining
potential risk factors for a hemoglobin decline and the rate
of hemoglobin decline would ideally be addressed by a pro-
spective RCT. All the data presented here are retrospective,
representing either an unplanned retrospective subgroup anal-
ysis of RCT data or retrospective EMR data. As such, the data
presented here are hypothesis-generating only.
The data reported here from placebo patients in RCTs
suggested that for patients receiving chemotherapy with a
hemoglobin decline to <10 g/dL, hemoglobin levels subse-
quently transition quickly to <9 g/dL. The proportion of
chemotherapy episodes where hemoglobin declined to
<9 g/dL was similar regardless of age. Consistent with the
known enhanced hematotoxicity in elderly patients [16, 17],
the hemoglobin decline was slightly more pronounced in
patients over 65 years. Despite expected differences be-
tween patients enrolled in global RCT trials 10 years ago
and patients currently being treated in US community
Table 2 Proportion of patients with hemoglobin decline from <10 g/dL to <9 g/dL
Patients or episodes with hemoglobin
decline, % (95 % CI)







Episodes with a platinum
doublet (n03,489)
Week 3 40 % (35, 45) 35 % (34, 37) 42 % (40, 44) 40 % (38, 41)
Week 6 54 % (49, 59) 43 % (41, 44) 48 % (46, 51) 47 % (46, 49)
Week 9 58 % (53, 63) 46 % (44, 47) 51 % (49, 54) 51 % (49, 53)
a Values represent Kaplan–Meier percentage estimates
b Values represent crude percentages
RCT randomized controlled trials, EMR electronic medical records
CI confidence interval
Fig. 1 Time to hemoglobin
decline from <10 g/dL to <9 g/
dL in patients enrolled in RCTs.
The Kaplan–Meier analysis of
time to hemoglobin decline is
shown. Gray shading
represents 95 % confidence
intervals
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oncology practices, patients with the same tumor types and
receiving similar chemotherapy doublets experienced simi-
lar rates of hemoglobin decline.
Most of the placebo patients enrolled in the RCTs had
lung cancer and/or had received platinum chemotherapy,
whereas many cancer types were represented in the EMR
database and the most common chemotherapy was taxane.
The predominant cancer type represented in the EMR data-
base was breast cancer. Also, EMR patients were treated in
2008–2010 and there may have been some shift in chemo-
therapy regimens compared with the time frame of the RCTs
(late 1990s to early 2000s). Despite differences in study
populations, including tumor types and chemotherapy regi-
mens, the proportion of patients who experienced a hemo-
globin decline from >10 g/dL to <9 g/dL was quite similar
in the RCT and EMR database patients. The decline to <9 g/
dL occurred within 3 weeks in 35 % to 40 % of patients and
43 % to 54 % by 6 weeks. In the RCT dataset, the Kaplan–
Meier estimate of transfusion rate was 20 % (95 % CI0
16 %, 24 %) within 3 weeks and 32 % (95 % CI027 %,
36 %) within 6 weeks.
A strength of this analysis is the consistent results
obtained with both the pooled RCT data and the real-
world observational EMR data. Limitations of the use of
EMR data for our analysis include a potential selection bias
due to the voluntary provision of data by oncology practices
(treatment patterns may be different in practices that do not
participate), and the lack of data for treatments and proce-
dures that are not reimbursable. For example, information
on transfusions, inpatient chemotherapy, and oral chemo-
therapy (for which patients are sent elsewhere) as well as
any procedures that occur in a hospital setting (e.g., trans-
fusions) are not included in the EMR database. Therefore,
the lack of transfusion data in the EMR did not allow us to
determine if the correlation between the RCT and EMR data
for hemoglobin decline from <10 g/dL to <9 g/dL also held
for the time to first transfusion. Furthermore, this study did not
address if specific populations of patients may be more likely
to avoid a continued decline in their hemoglobin with a
specific intervention, such as an ESA. Patients were required
to be iron replete upon entry into all but one of the RCTs;
however, although patients with other diagnosis codes for
anemia were not included in the EMR data set, as it is an
observational database, iron stores were not known.
It is interesting to note the similarity between the results of
the RCT and the EMR data base, despite the difference in
characteristics of the patients included in the two data sources.
Patients enrolled in RCTs represent a select population of
cancer patients. These patients tend to have no or few comor-
bidities and are also more likely to receive their chemotherapy
at the full dose and on schedule, although this was not a
specific requirement of these ESA clinical trials. In contrast,
patients in an EMR database may be more representative of
the general population and their treatment patterns may be
more representative of community oncology clinic dosages
and schedules. The similarity of results observed in the RCT
patients and EMR database suggest that the rate of hemoglo-
bin decline in this analysis can be generalized to most cancer
patients, regardless of tumor type when receiving common
myelosuppressive doublet chemotherapy regimens.
There are currently three options for treating chemotherapy-
induced anemia in patients with advanced stage cancer who
have hemoglobin levels between 9 g/dL and 10 g/dL. The first
option is to wait and watch for continued hemoglobin decline
and worsening of anemia symptoms. The second option, for
appropriate patients, is to initiate ESA therapy. The third option
is to undergo RBC transfusion. Each of these options is asso-
ciated with benefits and risks. The results of this analysis
suggest that for patients with hemoglobin between 9 g/dL and
10 g/dL who are planned to receive further myelosuppressive
chemotherapy, the first option of waiting and watching may
result in over a third of patients falling to hemoglobin <9 g/dL
within 3 weeks. The RCT data further suggest that 32 % will
need a transfusion within 6 weeks. Knowing that a potential
Fig. 2 Hemoglobin decline by age group in patients in the EMR
database. The proportion of all chemotherapy episodes (black bars),
episodes for patients ≥65 years of age (white bars), and episodes for
patients <65 years of age (gray bars) with hemoglobin decline from
<10 g/dL to <9 g/dL are shown
Table 3 Time to first transfusion from first hemoglobin <10 g/dL
Patients transfuseda, % (95 % CI) RCT patients (n0411)
Week 3 20 (16, 24)
Week 6 32 (27, 36)
Week 9 39 (35, 44)
Week 12 43 (38, 48)
RCT randomized controlled trials, CI confidence interval
a Values represent Kaplan–Meier percentage estimates
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hemoglobin response to ESAs takes time, waiting and watch-
ing may not be the optimal choice for patients with hemoglobin
between 9 g/dL and 10 g/dL who want to minimize their risk of
transfusion.
In summary, our results suggest that hemoglobin could rap-
idly declinewhen hemoglobin levels in cancer patients receiving
chemotherapy drop to around 10 g/dL. This decline in hemo-
globin was associated with a high rate of RBC transfusions.
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